Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,299.60
(
0.69%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.71
(
0.05%
)
Bitcoin
73,914.37
(
-0.04%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 86623

Monday, 11/23/2009 8:35:28 PM

Monday, November 23, 2009 8:35:28 PM

Post# of 257253
Re: RG7128 passes Phase 2b safety review

Given the prior safety signal, passing the interim review and proceeding to the second stage of the phase-2b trial is a significant milestone for VRUS, and it’s surprising the stock rose only 1% today.

With an enterprise value in the $500-600M range, VRUS is overpriced (IMO), but the positive safety review for RG7128 means it’s less overpriced today than it was yesterday.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now